Work

Financial toxicity, Part I: a new name for a growing problem.

Year: 2013

Type: article

Abstract: Costs of care continue to rise; new cancer drugs are more expensive than ever before, and more patients are being treated with these drugs. While patients and claims datasets consistently report an association between financial burden and quality of care, the impact on traditional disease-related outcomes—survival, for example—have not been assessed.

Source: PubMed

Authors: S Yousuf Zafar, Amy P Abernethy

Institutions: Duke University, Duke Cancer Institute, Duke Clinical Research Institute

Language: English

Topic: Economic and Financial Impacts of Cancer

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute

Award: Cancer Center Support Grant (CCSG)